Glaxosmithkline Share News (GSK)

GlaxoSmithKline: SUMMIT COPD Survival Study Fails To Meet Primary Point

Glaxo, Theravance Breo lung drug fails to extend life in huge study

Sept 8 (Reuters) - GlaxoSmithKline Plc and its partner Theravance Inc on Tuesday said their inhaled medicine Breo failed in a huge, high-stakes clinical trial to prolong life of patients with chronic pulmonary respiratory disease. Investors had hoped the 16,500-patient study, called SUMMIT

Broker tips: DMGT, Pearson, GSK

(ShareCast News) - Exane BNP Paribas downgraded Daily Mail & General Trust to 'neutral' from 'outperform' and cut its price target to 850p from 920p. It noted the stock's recent rebound, which has seen it outperform the media sector by around 10% in the last month following a precipitous drop in Jul

GSK gains as Merrill hikes rating on valuation and dividend yield

(ShareCast News) - Bank of America Merrill Lynch upgraded GlaxoSmithKline to 'neutral' from 'underperform' with an unchanged price target of 1,450p. It noted that the stock is now trading around 18% off its April highs and 8% below the bank's price target, offering approximately 14% total return wit

Pfizer's quit-smoking drug not linked to depression or heart risks

By Kate Kelland LONDON, Sept 7 (Reuters) - Pfizer's stop-smoking drug Chantix does not raise risks of heart attack or depression, contrary to previous reports, and should be recommended to more smokers wanting to quit, scientists said on Monday. In a study tracking 150,000 smokers in

UPDATE 1-FDA proposes adding suffixes to distinguish biosimilar drug names

(Adds industry, patient group comment) By Toni Clarke WASHINGTON, Aug 27 (Reuters) - The U.S. Food and Drug Administration proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts. The

FDA proposes adding suffixes to distinguish biosimilar drug names

WASHINGTON, Aug 27 (Reuters) - Cheaper versions of biologic drugs would be identified by a suffix to distinguish them from their more expensive, branded counterparts under draft guidance issued on Thursday by the U.S. Food and Drug Administration. The FDA said its proposal is designed to

BUZZ-U.S. STOCKS ON THE MOVE-Apple, SunEdison, HMS Holdings, Abercrombie

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock indexes were down on Monday. The Dow Jones industrial a

BUZZ-U.S. STOCKS ON THE MOVE-Bank stocks, tech stocks, AGL, ChinaCache

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock indexes were down on Monday. The Dow Jones industrial a

BUZZ-Healthcare stocks: Down on market selloff

** Shares of healthcare companies including drugmakers and biotechnology therapy developers fall about 3 pct as Wall Street opens sharply lower ** More than 8 pct drop in Chinese shares, selloff in oil and other commodities prompt downturn in all three stock market indices ** U.S.-lis

EU Commission clears Perrigo to buy GSK units

BRUSSELS, Aug 21 (Reuters) - The European Commission cleared on Friday U.S. drugmaker Perrigo's acquisition of certain assets from Britain's GSK. The Commission, in its role as the competition regulator in the 28-member European Union, said GSK would sell certain products such as cold and f

TOP NEWS SUMMARY: UK Records First July Budget Surplus Since 2012

LONDON BRIEFING: China And Greece Combine To Send Stocks Reeling

GSK extends Novartis disposal agreement

(ShareCast News) - GlaxoSmithKline has sold all the rights to its ofatumumab drug to Novartis for up to £1.03bn, extending a previous disposal agreement. GSK previously agreed to divest the drug's oncology indications and has now agreed to include its rights in ofatumumab for auto-immune indications

London pre-open: stocks set to plunge as China off the rails

(ShareCast News) - City sources predict the FTSE 100 will open 142 points lower than Thursday's close of 6,367.89. "European equities are set to plunge on the open as China goes off the rails," London Capital Group night dealer Jonathan Sudaria said. Sudaria said bulls were already slowed by a barr